Get the Stockscreener App
4.15
3.49%
0.14
Cytek Biosciences Inc stock is traded at $4.15, with a volume of 782.50K.
It is up +3.49% in the last 24 hours and up +27.69% over the past month.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
See More
Previous Close:
$4.01
Open:
$4.04
24h Volume:
782.50K
Relative Volume:
0.63
Market Cap:
$527.98M
Revenue:
$193.01M
Net Income/Loss:
$-12.15M
P/E Ratio:
-46.11
EPS:
-0.09
Net Cash Flow:
$454.00K
1W Performance:
+3.49%
1M Performance:
+27.69%
6M Performance:
-18.95%
1Y Performance:
-20.65%
1-Day Range:
$4.04
$4.275
1-Week Range:
$3.91
$4.275
52-Week Range:
$2.37
$7.63
Cytek Biosciences Inc Stock (CTKB) Company Profile
Name
Cytek Biosciences Inc
Sector
Industry
Phone
(877) 922-9835
Address
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
4.15 | 516.53M | 193.01M | -12.15M | 454.00K | -0.09 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-09-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-31-25 | Downgrade | Goldman | Buy → Sell |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Jul-19-23 | Initiated | Raymond James | Mkt Perform |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
Cytek Biosciences Inc Stock (CTKB) Latest News
Will Cytek Biosciences Inc. rebound enough to break evenEarnings Miss & Low Drawdown Momentum Trade Ideas - Newser
Cytek Biosciences Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingTake Profit & Weekly Setup with ROI Potential - beatles.ru
Cytek Biosciences Inc. Shows Early Signs of Technical StrengthWatch List & AI Enhanced Trade Execution Alerts - thegnnews.com
What is the long term forecast for Cytek Biosciences Inc. stockQuarterly Portfolio Review & Expert Curated Trade Setups - newsyoung.net
What makes Cytek Biosciences Inc. stock price move sharplyWeekly Trend Report & Growth Focused Entry Point Reports - 선데이타임즈
Is Cytek Biosciences Inc. stock a buy or sellEarnings Risk Summary & Weekly Chart Analysis and Guides - mustnews.co.kr
Cytek Biosciences, Inc. (NASDAQ:CTKB) Stock Catapults 26% Though Its Price And Business Still Lag The Industry - simplywall.st
Can Cytek Biosciences Inc. weather a recessionJuly 2025 Volume & High Conviction Investment Ideas - thegnnews.com
Published on: 2025-08-15 05:10:44 - theviewers.co.kr
Cytek Biosciences Inc. Recovery Linked to Earnings SurpriseQuarterly Risk Review & Growth Focused Stock Pick Reports - mustnews.co.kr
Cytek Biosciences at UBS Summit: Innovative Proteomics Insights By Investing.com - Investing.com South Africa
Cytek Biosciences Inc. Ranks High in Smart Money TrackerWeekly Earnings Recap & Daily Stock Trend Reports - 선데이타임즈
Cytek Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire
Cytek Biosciences Showcases Cell Analysis Innovation at UBS, Wells Fargo, Morgan Stanley Events - Stock Titan
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cytek Biosciences (CTKB), Natera (NTRA) and Warby Parker (WRBY) - The Globe and Mail
Mixed Analyst Opinions on Healthcare Stocks Cytek Biosciences, Natera, and Warby Parker - AInvest
Cytek Biosciences Earnings Call Reveals Mixed Outlook - TipRanks
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q2 2025 Earnings Call Transcript - Insider Monkey
Cytek Biosciences Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Cytek Biosciences Narrows FY25 Revenue Guidance to $196M-$200M - AInvest
Cytek narrows 2025 revenue outlook to $196M-$205M amid recurring revenue growth and new product launches - MSN
Cytek Biosciences 2025 Q2 Earnings Loss Narrows 50% as Revenue Slides 2.2% - AInvest
Cytek Biosciences Narrows 2025 Revenue Outlook to $196M-$205M Amid Recurring Revenue Growth and New Product Launches - AInvest
Cytek's 2025 Q2 Earnings: Navigating Contradictions in Sales, Margins, and Market Growth - AInvest
Earnings call transcript: Cytek Biosciences Q2 2025 misses revenue forecast By Investing.com - Investing.com Canada
Earnings call transcript: Cytek Biosciences Q2 2025 misses revenue forecast - Investing.com India
Cytek Biosciences: Q2 2025 Financial Performance Overview - TipRanks
Cytek Biosciences, Inc. (CTKB) Beats Q2 Earnings Estimates - sharewise.com
Transcript : Cytek Biosciences, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Cytek Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cytek Biosciences, Inc. SEC 10-Q Report - TradingView
Cytek Biosciences earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada
Cytek Biosciences Reports Second Quarter 2025 Financial Results - GlobeNewswire
Cytek Biosciences Inc. Stock Analysis and ForecastTremendous gains - Jammu Links News
How does Cytek Biosciences Inc. compare to its industry peersMaximize your returns with smart trade entries - Jammu Links News
Is Cytek Biosciences Inc. a growth stock or a value stockBuild a winning portfolio with smart picks - Jammu Links News
What are the technical indicators suggesting about Cytek Biosciences Inc.Breakthrough capital growth - Jammu Links News
Does Cytek Biosciences Inc. stock perform well during market downturnsHigh-profit stock alerts - Jammu Links News
Should I hold or sell Cytek Biosciences Inc. stock in 2025Invest confidently with professional market insights - Jammu Links News
Is it the right time to buy Cytek Biosciences Inc. stockBuild your wealth with consistent stock growth - Jammu Links News
What catalysts could drive Cytek Biosciences Inc. stock higher in 2025Discover stock picks with superior returns - Jammu Links News
How strong is Cytek Biosciences Inc. company’s balance sheetFree Expert Stock Watchlist - Jammu Links News
What are the latest earnings results for Cytek Biosciences Inc.Capitalize on fast-moving trading opportunities - Jammu Links News
Can machine learning forecast Cytek Biosciences Inc. recoverySafe Momentum Strategy With Trend Analysis - Newser
Multi asset correlation models including Cytek Biosciences Inc.Institutional Holding Behavior Pattern Analysis - Newser
Using Bollinger Bands to evaluate Cytek Biosciences Inc.Real-Time AI Sentiment and Price Forecast - Newser
Real time social sentiment graph for Cytek Biosciences Inc.Free Weekly Hot Picks With Buy Confidence - Newser
Cytek Biosciences Inc.’s volatility index tracking explainedTrade Setups With AI Powered Filters Published - metal.it
Cytek Biosciences Inc Stock (CTKB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytek Biosciences Inc Stock (CTKB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McCombe William D. | Chief Financial Officer |
Jun 02 '25 |
Buy |
2.78 |
35,000 |
97,300 |
55,746 |
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):